Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LAM202403: Laminar Left Atrial Appendage Elimination (LAAX) Pivotal IDE Study

NCT06168942 is registered in ClinicalTrials.gov with Biosense Webster, Inc. as lead sponsor.

NCT NCT06168942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06168942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LAM202403: Laminar Left Atrial Appendage Elimination (LAAX) Pivotal IDE Study
Lead sponsor
Biosense Webster, Inc.
Phase
Not applicable
Overall status
Suspended
Start date
February 19, 2024
Completion date
February 29, 2032
Enrollment
1,500 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

non-valvular atrial fibrillation, stroke, systemic embolism